A Major Player Makes a Bold Move in the Obesity Drug Race

A heavy weight in global pharmaceuticals is doubling down on obesity treatments, striking a sweeping agreement to secure the rights to a promising early-stage pill.

The deal marks a decisive step in a market where demand is only accelerating.

Easy Trading (Sponsored)

Your Upgrade to Stress-Free Trading Starts Here

Today’s brokers simplify everything from research to execution.

Fractional shares let you start small.

Clean dashboards help you stay organized.

Low-fee trades make it easy to stay active without overspending.

If you want an easier way to invest smarter, check out the platforms built for real people, not experts.

DISCOVER EASY-TO-USE BROKERS

Never Miss a Stock Recommendation Again!

We now send our dividend picks right to your phone via text, so you’ll get the same actionable moves without having to open your inbox.

👉 Click here to get our dividend picks by text and keep our content right at your fingertips.

Global Expansion

Nike Isn’t Just Signing Players Anymore

Nike (NYSE: NKE) just made a move that hits far harder than a simple kit deal.

By locking in a long-term partnership with Brazilian club Vasco, Nike is planting a flag in one of the most influential football cultures in the world.

You see a sponsorship on the surface, but Nike sees a launchpad for global storytelling, athlete pipelines, and lifestyle expansion.

Vasco’s fan base is massive, loyal, and culturally embedded across Brazil and beyond.

Nike's attachment to that ecosystem gives the brand fresh creative territory at a time when every sports company is trying to stay relevant.

Where Jersey Deals Become Global Strategy

This agreement goes far deeper than the logo on the shirt.

Nike will build full product lines for men, women, youth, staff, and lifestyle, turning Vasco into a year-round retail engine instead of a seasonal kit partner.

Football’s global surge makes this timing perfect. Brazilian talent drives the sport’s global identity, and Nike now sits closer to the next generation of stars and stories.

Nike’s Push Into the Next Decade

This move strengthens Nike’s presence in markets it wants to dominate, especially as apparel tied to football culture keeps outperforming.

When Vasco’s branding travels through Nike’s global channels, you’re looking at a fusion of sport and streetwear built to hit multiple continents at once.

For Nike, this is not just a sponsorship. It is a strategic expansion play disguised as a jersey launch.

NKE currently trades at $64 and pays a dividend of $1.64 per share, a yield of 2.53%

Enterprise

The AI Buildout That Forces Oracle Into Its Toughest Test Yet

Oracle (NYSE: ORCL) is moving into a phase where big promises collide with real execution, placing you squarely in the middle of the company’s toughest proving ground yet.

After months of hype built on backlog records and its OpenAI alliance, the storyline is shifting toward accountability.

Scrutiny is rising fast because Oracle’s AI narrative now depends on results, not optimism. This is where the company must show its ambition can survive real-world pressure.

The Spend That Redraws the Risk Map

Oracle’s AI push sits on a datacenter buildout happening alongside more than $400 billion in global infrastructure spending, and that scale forces you to notice how carefully the company must balance its debt and demand curves.

Much of the investment is tied to securing compute for OpenAI, a move that only works if enterprise adoption deepens rapidly.

Oracle Stands on the Edge of a Complete Identity Shift

If Oracle hits its marks, you watch a legacy enterprise company transform into a backbone of the generative AI era with sticky, long-term revenue.

Success here would shift Oracle into a new tier of global relevance.

But if the economics slip, the downside becomes difficult to ignore and momentum gets harder to recapture.

This is the fork in the road that defines whether Oracle’s AI vision becomes a breakthrough or a cautionary tale.

ORCL currently trades at $220 and pays a dividend of $2.00 per share, a yield of 0.91%.

Outperformers (Sponsored)

The 5 Stocks Likely to Outperform in the Year Ahead

After reviewing thousands of companies, analysts isolated the 5 Stocks Set to Double based on accelerating performance, improving fundamentals, and strong technical signals.

This newly released report breaks down why these five picks may be positioned for significant moves in the coming year.

While results cannot be guaranteed, past reports uncovered gains reaching +175%, +498%, and +673%.

Access is free until midnight.

See the 5 Stocks Set to Double. Free Access.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Biopharma

The Pill That Could Change Pfizer’s Entire Future

Pfizer (NYSE: PFE) just signed a licensing deal worth up to $2.1 billion with China’s YaoPharma, and this instantly rewrites the company’s role in the global obesity drug race.

What looks like a pipeline update is actually Pfizer rebuilding its strategy from the ground up.

The market context makes this even louder.

Obesity drugs are set to surpass $100 billion in annual value by the 2030s, and Pfizer is refusing to sit on the sidelines while competitors lock in early advantage.

A New Shot at the GLP-1 Crown

The drug targets the powerful GLP-1 pathway, but because it is an oral pill, Pfizer is positioning itself in the part of the market expected to see the widest adoption.

Oral treatments open a way to consumers who never choose injectables, and that is where you see the strategy sharpen.

Instead of relying on a single experimental asset, Pfizer is building a multi-drug pipeline that spreads risk and multiplies opportunity.

Building a Two-Track Obesity Empire

This move pairs perfectly with Pfizer’s recent $10 billion Metsera acquisition, giving the company both internal development strength and external firepower.

When you look across these deals together, the message is unmistakable: Pfizer is gearing up for long-term dominance, not short bursts of momentum.

For Pfizer, this shift signals a company preparing to win across metabolic disease, combination therapies, and next-generation obesity medicine.

PFE currently trades at $25 and pays a dividend of $1.72 per share, a yield of 6.78%.

AMGN has raised its dividend to $2.52, an increase of 5.88%. Its new yield is 3.21%.

LLY has increased its dividend to $1.73, up 15.33%. Its new yield is 0.7%.

IMMR has increased its dividend to 7 cents, up 66.67%. Its new yield is 4.26%. 

GGG has raised its dividend to 29 cents, up 7.27%. Its new yield is 1.42%.

PCAR has cut its dividend to 33 cents, a 76.43% reduction. Its new yield is 1.21%.

Clear Signal (Sponsored)

A Market Indicator That Cuts Through the Noise

When he appeared on live TV and made a bold prediction, the hosts couldn’t believe it.

But when the market moved exactly as he said, people started paying attention.

His secret? A simple trading indicator that shows clear buy and sell moments — without guesswork or emotion.

He’s used it for 30 years.

It guided him through every kind of market.

And now, he’s sharing it for free.

This same indicator has flashed again… and what it’s showing might surprise you.

[Get the free indicator here]

Everything Else

• Paramount Skydance has launched a hostile $108.4 billion bid for Warner Bros Discovery, seeking to unseat Netflix in the running for the studio's TV, film, and streaming assets.

• Target has thrown open the doors to a new shoppable concept store in New York’s Soho. Designed as an immersive experience, Target SoHo is described as the first step in the retailer’s ‘design-driven future’.

• Starbucks workers from as far afield as England, Germany, Brazil, and Australia held protests today (Wednesday) in support of the ongoing Starbucks Workers United strike action in the USA. 

• Eli Lilly will invest $6 billion to build a new factory in Huntsville, Alabama. The new facility will be used to boost production of the company’s obesity drugs.